Medically reviewed by Jamin Brahmbhatt, MD Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced ...

ORIC Pharmaceuticals (ORIC) updated investors on Phase 1b data for rinzimetostat plus darolutamide in metastatic castration resistant prostate cancer, and selected a 400 mg daily dose for a planned ...

An exposure-response analysis showed a statistically significant link between higher drug exposure and increased toxicities ...

Akeega reduced radiographic progression or death risk by 37% in mCSPC patients with HRR gene alterations. Significant reduction in symptomatic progression risk by 50% and a trend towards improved ...

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...

When compared to tumors from European American men with mCRPC, African American men with mCRPC demonstrated a higher expression of MYC pathway genes and lower expression of IFN-γ, IL-6/JAK/STAT3 and ...

Transdermal oestradiol patches are non-inferior to luteinising hormone-releasing hormone agonists for metastasis free survival in locally advanced prostate cancer, a study shows.

Shares of Oric Pharmaceuticals fell after the company said data from a phase 1b trial of a prostate cancer treatment showed that a larger dose led to higher rates of side effects. Shares were down 22% ...